Comparing NeuroBo Pharmaceuticals (NASDAQ:NRBO) and InterCure (NASDAQ:INCR)

InterCure (NASDAQ:INCR) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Profitability

This table compares InterCure and NeuroBo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%

Analyst Recommendations

This is a summary of current ratings and recommmendations for InterCure and NeuroBo Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0	0	0	0	0.00
NeuroBo Pharmaceuticals	0	0	1	0	3.00

NeuroBo Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 356.62%. Given NeuroBo Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe NeuroBo Pharmaceuticals is more favorable than InterCure.

Volatility & Risk

InterCure has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.

Institutional and Insider Ownership

8.3% of InterCure shares are owned by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares InterCure and NeuroBo Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$272.67 million	0.22	-$16.83 million	N/A	N/A
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A

NeuroBo Pharmaceuticals has lower revenue, but higher earnings than InterCure.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.